|
Gemcitabine HCI
API |
|
|
|
Haorui supplies high quality Gemcitabine HCI API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Gemcitabine HCI API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
|
|
|
What is Gemcitabine HCI? |
|
Gemcitabine is a chemotherapy
drug that is given as a treatment for some types of
cancer. Gemcitabine is most commonly used to treat non
small cell lung cancer, pancreatic, and bladder cancer.
|
|
|
|
How does Gemcitabine HCI work?
|
|
Gemcitabine, a
pyrimidine analog, is structurally similar to cytarabine,
but has a wider spectrum of antitumour activity due to
its different cellular pharmacology and mechanism of
action. Gemcitabine is metabolized intracellularly to
two active metabolites, gemcitabine diphosphate (dFdCDP)
and gemcitabine triphosphate (dFdCTP). The cytotoxic
effects of gemcitabine are exerted through incorporation
of dFdCTP into DNA with the assistance of dFdCDP,
resulting in inhibition of DNA synthesis and induction
of apoptosis. Gemcitabine is a radiation-sensitizing
agent. It is cell-cycle phase specific (S and G1/S-phases). |
|
|
|
What is Gemcitabine HCI used for?
|
 |
· Lung
cancer, non-small cell |
|
· Pancreatic
cancer |
|
· Bladder
cancer |
|
· Breast
cancer |
|
· Cervical
cancer |
|
· Head
and neck cancer |
|
· Lung
cancer, small cell |
|
· Lymphoma,
cutaneous T-cell |
|
· Lymphoma,
Hodgkin’s disease |
|
· Mesothelioma |
|
· Ovarian
cancer |
|
|
|
|
Gemcitabine HCI dosage guideline
|
|
Refer to
protocol by which patient is being treated. Numerous
dosing schedules exist and depend on disease, response
and concomitant therapy. Guidelines for dosing also
include consideration of absolute neutrophil count
(ANC). Dosage may be reduced, delayed or discontinued in
patients with bone marrow depression due to cytotoxic/radiation
therapy or in patients with other toxicities. |
|
|
|
Precautions of Gemcitabine HCI |
| |
|
While you are
being treated with gemcitabine, and after you stop
treatment, do not have any immunizations (vaccinations)
without your doctor’s okay. Try to avoid contact with
people who have recently taken the oral polio vaccine.
Check with your doctor about this. |
| |
|
Gemcitabine
can lower your blood counts (white blood cells, red
blood cells, platelets). Your doctor will check your
blood counts before and after each treatment to see how
it affects your blood counts. Your doctor or nurse will
give you specific instructions if your blood counts are
low. |
| |
|
Gemcitabine
can decrease your white blood cell count, especially 10
to 14 days after the drug is given. This can increase
your risk of getting an infection. Report fever of
100.5°F or higher, or signs of infection such as pain in
passing your urine, coughing, and bringing up sputum. |
| |
|
Gemcitabine
can decrease the platelet count. This can increase your
risk of bleeding. DO NOT take any aspirin or
aspirin–containing medicines. Report unusual bruising,
or bleeding such as nosebleeds, bleeding gums when you
brush your teeth, or black, tarry stools. |
|
|
|
Gemcitabine HCI side effects
|
|
· Temporary
reduction in the production of blood cells.This
can result in anaemia leading to tiredness; an increased
risk of bruising or bleeding and an increased risk of
infection.
· Nausea
(feeling sick) and vomiting
This is usually mild and there are now very effective
anti-sickness drugs which can prevent or greatly reduce
nausea and vomiting. If you do feel sick this will
usually begin a few hours after the treatment is given
and may last for up to a day. If the sickness is not
controlled, or continues, tell your doctor. They can
prescribe other anti-sickness drugs that may be more
effective.
· Loss
of appetite
This is usually mild and may last a day or so.
CancerBACUP has a section on diet and the cancer
patient, which has tips on boosting your appetite,
coping with eating difficulties and maintaining weight.
The dietitian at the hospital can be very helpful.
· Temporary
effect on liver function
Gemcitabine may cause changes in the way that your liver
works, which return to normal when the treatment is
finished. You are very unlikely to notice any problems
but your doctor will check your liver function before
each treatment.
· Change
in kidney function
Some people have a small amount of blood or protein in
their urine when it is tested. You are very unlikely to
notice any change and it is unlikely to cause any harm.
· Skin
changes
Gemcitabine can cause a rash, which may be itchy. Your
doctor can prescribe medicines to relieve the symptoms.
You may also notice some swelling of your ankles. This
is usually mild and goes away after the treatment ends.
· Flu-like
illness
Occasionally a flu-like illness may occur with
gemcitabine. You may have headaches, aching joints and
muscles and a high temperature. You should always let
your doctor know about a high temperature immediately.
·
Fluid retention
This may cause swelling of the ankles or breathlessness.
Let your doctor know if you notice this effect.
· Tiredness
and a general feeling of weakness
It is important to allow yourself plenty of time to
rest. |
|
|
|
Gemcitabine HCI Special Conditions To
Observe |
|
Gemcitabine may cause
drowsiness. Take care if you are driving or operating
machinery following this treatment.
Fertility
Your ability to become pregnant or father a child may be
affected by taking this drug. It is important to discuss
fertility with your doctor before starting treatment.
Contraception
It is not advisable to become pregnant or father a child
while taking gemcitabine as it may harm the developing
foetus. It is important to use effective contraception
whilst taking this drug, and for at least a few months
afterwards. Again, discuss this with your doctor. |
|
|
|
Disclaimer:
|
|
Information on this page is provided
for general information purposes. You should not make a
clinical treatment decision based on information
contained in this page without consulting other
references including the package insert of the drug,
textbooks and where relevant, expert opinion. We cannot
be held responsible for any errors you make in
administering drugs mentioned on this page, nor for use
of any erroneous information contained on this page.
|
|
|
